PSNL · Personalis, Inc. · Stock research

Prices referenced are split/dividend-adjusted daily closes; the reference close is $18.38 on 2026-08-21.

PSNL — Personalis, Inc.

Current Thesis

The August update changes the question from "does the deal close?" to "why is the stock trading above what the deal pays?" On 2026-08-19 Merck and Moderna reported that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint and the distant metastasis-free survival secondary in 1,137 patients with completely resected stage IIB–IV melanoma — the first positive Phase 3 for an individualized neoantigen therapy. Tempus AI (TEM), the acquirer, rose 24.1% on 2026-08-19 and a further 8.8% on 2026-08-20 to close $66.65, an equity-value gain reported at roughly $3.03B, about 2.02x the $1.5B headline deal size (ts2.tech, 2026-08-20). Personalis closed $18.38 on 2026-08-21, a 52-week high, with RSI(14) at 81.7 and a three-month price change of +117.0%.

The merger terms did not move. Under the 2026-07-20 agreement the exchange ratio is capped at 0.3356 Tempus Class A shares and applies only when Tempus's measured price is at or below $48.42; above that level the ratio equals $16.25 divided by the Tempus price, which fixes consideration at $16.25 per share. Tempus may separately elect cash for up to 50% of shares, also at $16.25. With Tempus near $66.65, the implied ratio is roughly 0.244 (arithmetic on two published figures; the binding ratio is set off a measured price near closing, not today's quote). The last close therefore sits $2.13 above the contractual maximum.

What an investor buys at $18.38 is not the spread and not the ratio. It is a claim that the signed price is stale — that a superior proposal appears, that the holder base declines to adopt, or that a broken deal leaves a re-rated MRD franchise. Nothing in the filed terms delivers more than $16.25.

The narrative is saturated. Dated by 2026-07-20, when definitive terms capped the outcome distribution, and re-confirmed on 2026-08-21, when the tape moved above that cap with no change to the agreement and no competing bid on file. The underlying theme — individualized neoantigen therapy plus MRD monitoring — is accelerating on the 2026-08-19 readout, but under the filed structure that acceleration accrues to Tempus's share count, not to an uncapped claim held by Personalis holders.

Bullish and bearish views on Personalis, Inc.

The model's bull view on Personalis, Inc. (PSNL), in brief: 2026-08-19 readout validates the end market Personalis sequences for. The bear view: Consideration is capped at $16.25 and the last close is $18.38. Both cases follow in full.

Bull Case

• 2026-08-19 readout validates the end market Personalis sequences for. INTerpath-001 met RFS and DMFS in 1,137 patients randomised 2:1 to intismeran 1 mg q3w (≤9 doses) plus roughly one year of pembrolizumab versus pembrolizumab alone (Merck/Moderna release). ts2.tech reported 2026-08-20 that Personalis supplies the genomic sequencing used in the individualized-vaccine program; Merck was 19% of Q1 2026 revenue, consistent with that role.
• The acquirer's own market cap moved by ~2x the deal size on target-adjacent news (2026-08-20). A $3.03B equity gain against a $1.5B transaction is the argument a dissenting holder makes that $16.25 no longer reflects the asset.
• The vote has not happened. The Form S-4 and proxy statement-prospectus were not effective as of 2026-08-23; no special meeting has been calendared. Merck's ~13% is committed by voting agreement, leaving the balance of the register to decide adoption.
• Q2 removed the operational-deterioration argument (2026-08-04). Revenue $22.357M against $16.783M consensus, +30% YoY from $17.2M; clinical diagnostic revenue $2.6M (+442% YoY); NeXT Personal clinical tests 10,384, +199% YoY and +33% sequential.
• Standalone runway if the deal fails. $212.7M in cash and short-term investments at 2026-06-30 ($94.0M cash, $118.7M short-term investments) against a Q2 net loss of $31.7M. A new VA MVP task order announced 2026-08-20, effective 2026-09-30, is valued up to $18.30M.

Bear Case

• Consideration is capped at $16.25 and the last close is $18.38. Above a $48.42 Tempus price, every dollar Tempus gains reduces the shares delivered. Tempus at ~$66.65 on 2026-08-20 is well clear of that threshold, so the ratio floats down while the value stays pinned.
• The structural obstacles to a topping bid are on file (2026-07-20): termination fees of approximately $76.8M running both ways, and a voting agreement from Merck — itself a prior suitor per StreetInsider's 2026-07-17 reporting — supporting the Tempus deal.
• A failed vote removes the floor, not just the cap. Personalis withdrew FY2026 guidance and discontinued quarterly earnings calls on 2026-08-04. A break leaves a loss-making company with no published forward numbers into a tape that has already priced a takeout.
• Time works against a negative spread. The parties expect closing in late 2026 or early 2027; the outside date is 2027-04-20 with automatic six-month extensions. Every month to close is carry against a fixed $16.25.
• Momentum extension is measurable. RSI(14) 81.7 at the 52-week high, with the price up 117.0% over three months and the 2026-08-14 close at $14.04 — the entire premium to the cap was built in four sessions.

Setup & Price Structure

The $16.25 contractual maximum is the structural reference the chart now trades around, and on 2026-08-21 the close was above it for the first time. The 2026-08-19/20 gap runs from roughly the $14 shelf established after the 2026-08-04 print to $18.38, leaving unfilled air between the readout gap and the deal cap. A weekly close back below $16.25 would mean the market has stopped paying anything for a bump-or-break outcome and is discounting the filed terms again; sustained trade above $16.25 is the observable that a competing-bid or vote-down probability is being underwritten.

Positioning observables, stated as observables: RSI(14) at 81.7 is the most extended reading in the covered period; the 52-week high and the last close are the same number, meaning there is no overhead supply from the past year; the move is acquirer-driven, so Personalis's daily prints have been set by a security whose own 52-week range is $40.77–$104.32 and whose 14-analyst consensus target was $62.64 as of 2026-08-20 (MarketBeat) — below where Tempus traded on 2026-08-23. There is no Personalis earnings date to trade into: calls were discontinued 2026-08-04. No insider transactions or issuance into this move have appeared in the filings reviewed through 2026-08-23; the absence is worth re-checking after the S-4 posts, since deal filings often surface holder activity that daily news does not.

Catalyst Calendar (next 30 days)

• TBD — follows S-4 effectiveness: Personalis special meeting to adopt the merger agreement. Majority-vote condition; Merck's ~13% is committed, so the remaining register decides.
• TBD — HSR filing date undisclosed: antitrust clearance for two overlapping precision-oncology genomics businesses.
• 2026-09-30: new VA MVP task order becomes effective, valued up to $18.30M (announced 2026-08-20) — the only dated company-specific item on the calendar.
• ~2026-11-04 (est.): Tempus AI Q3 2026 results, inferred from the 2026-07-30 Q2 release date and unconfirmed.

Elapsed catalysts

• TBD — not effective as of 2026-08-23: Tempus Form S-4 / proxy statement-prospectus (StockTitan's summary of the parties' Form 425 communications also references a joint Schedule 13E-3). Effectiveness publishes the background of the process and the board's financial analyses — the first document that lets an outsider judge $16.25 against the alternatives considered. (passed 3d ago)
• ~Q4 2026 (est., not announced as of 2026-08-23): full INTerpath-001 dataset presentation at a medical meeting. Topline was released 2026-08-19; effect sizes have not been published. (passed 3d ago)

What Would Change Our Mind

The frame breaks if the premium to the filed terms turns out to be information rather than momentum. A superior proposal disclosed in an 8-K, a Tempus amendment raising the $16.25 figure, or a background section in the S-4 showing a higher bid was on the table would all argue the market read the situation correctly and this note read it too literally. Equally, the frame breaks in the other direction if the S-4 goes effective, the meeting is calendared, and the vote carries with no competing bid — at which point the equity converges to a fixed number and the trading question is closed.

The gradeable version: a weekly close below $16.25 would show the premium to the contractual maximum has been priced out and the deal terms are governing the tape again. Secondary conditions: no superior proposal disclosed by the time the special meeting is calendared, or an 8-K confirming the vote carried on the existing terms. On the other side, Tempus's measured price falling under $48.42 would re-activate the fixed 0.3356 ratio and re-couple Personalis to Tempus's tape one-for-one — Tempus's own 52-week low of $40.77 shows that is inside its recent range.

Correlation Notes

• Tempus AI (TEM) is the mechanical driver below $48.42 and, in theory, irrelevant above it. That Personalis rose alongside Tempus on 2026-08-19/20 despite the value cap is the clearest evidence the market is pricing something other than the exchange ratio.
• Merck (MRK) and Moderna (MRNA) set the end-market narrative. The 2026-08-19 INTerpath-001 readout is the sequencing-demand catalyst; Merck is simultaneously Personalis's largest customer (19% of Q1 2026 revenue, 33% of receivables), a ~13% voting holder, and a committed supporter of the Tempus deal.
• MRD comparables — Natera, Guardant Health, Exact Sciences — carry the read-through on tumour-informed monitoring volumes, but Personalis's own price is now anchored to a contract rather than to sector multiples.
• Federal sequencing budgets remain a discrete exposure through the VA Million Veteran Program: population sequencing revenue was $3.0M in Q2 2026, down 9% YoY, before the up-to-$18.30M task order effective 2026-09-30.